Stocklytics Platform
Asset logo for symbol JSPR
Jasper Therapeutics
JSPR60
$4.56arrow_drop_up4.80%$0.20
Asset logo for symbol JSPR
JSPR60

$4.56

arrow_drop_up4.80%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Jasper Therapeutics (JSPR) Stocklytics Forecast

Jasper Therapeutics, Inc. (JSPR) is a leading biotechnology company focused on developing innovative therapies for severe diseases. As a pioneer in the field of cell therapy, JSPR has been at the forefront of groundbreaking research and development. With a strong pipeline of potential treatments, JSPR is poised for significant growth in the coming years.
The stock price of JSPR is subject to various factors, including market conditions, clinical trial results, regulatory approvals, and competition. As a result, it is difficult to predict the exact stock price of JSPR. However, analysts and experts have provided forecasts and price targets based on their evaluations and analyses.
add Jasper Therapeutics to watchlist

Keep an eye on Jasper Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Jasper Therapeutics (JSPR) stock?

Analysts have set a target price of $19.49 for Jasper Therapeutics (JSPR), based on forecasts from 28 analysts. The predicted price range extends from a high of $80 to a low of $3. This represents a potential increase of up to 1.65K% and a decrease of -34.21% from the current price of $4.56. These forecasts are as of 2022 May 13.
help

What are the analyst ratings for Jasper Therapeutics (JSPR) stock?

Currently, there are no analyst ratings available for Jasper Therapeutics (JSPR), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Jasper Therapeutics (JSPR) stock?

At present, there is no AI or machine-learning-based price prediction available for Jasper Therapeutics (JSPR) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level